Lineage Cell Therapeutics Q2 FY26 net income turns to USD 1.5 million; revenue falls 61.34% to USD 1.07 million
Reuters2026/08/06 20:04- Lineage Cell Therapeutics posted GAAP net income of $1.5 million, swinging from a net loss of $30.5 million a year earlier; basic EPS was $0.01.
- Revenue fell 61.34% to $1.1 million, due to lower Roche collaboration revenue recognition and lower VAC-related revenue; WDI collaboration revenue partly offset.
- Operating loss narrowed 54.9% to $8.9 million, on total operating expenses falling 55.69% to $10 million due to the prior-year $14.8 million VAC impairment.
- Cash, cash equivalents, and marketable securities totaled $50.8 million at June 30, expected to fund operations into Q3 2028.
- Genentech’s Phase 2a GAlette study for RG6501 remained active at 17 sites; COR1 advanced to in-vivo testing with initial preclinical data expected in 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
